FDA Enforcement and AI in Pharmaceutical Manufacturing
FDA enforcement activity related to artificial intelligence in pharmaceutical manufacturing has escalated significantly in 2024 and 2025. Warning letters, Form 483 observations, and import alerts have increasingly cited AI-related quality system failures — not as a new violation category, but as a new mechanism through which existing GxP violations are occurring.
The FDA's approach is instructive: it is not creating AI-specific regulatory requirements separate from its GxP framework. It is applying existing data integrity, CAPA and process validation expectations to AI systems — and finding that most pharmaceutical organisations have not extended quality system controls to cover AI's specific characteristics.
GAMP 5 and AI validation specialists. Gap assessment within 48 hours.